Answers are grounded in this paper and cite their sources.
Assesses T-DXd efficacy in HER2-positive metastatic breast cancer, suggesting new treatment strategies.
response, or partial response/stable disease with maximum tumor shrinkage).Secondary endpoints included best overall response and time to treatment failure (TTF), using the Kaplan-Meier method.Results: A total of 106 patients were included in the analysis.The median age was 58 years (range: 28-82).HR-positive and -negative tumors accounted for 60% and 40% of cases, respectively.T-DXd was administered as first-line therapy in 5%, second line in 20%, with a median line of therapy of 3. Brain metastases at baseline were present in 26%.The median TTMR was 4.85 months (95% confidential interval [CI]: 3.73-6.63).The median TTF was 18.9 months (95% CI: 12.4-24.0).The overall response rate was 56% (CR 6%, PR 50%).No difference in TTMR was observed across subgroups defined by hormone receptor status or line of therapy.We plan to present the results including additional patient data at the conference. Conclusions:In this multicenter real-world cohort of patients with HER2-positive metastatic breast cancer, T-DXd induced rapid tumor shrinkage, achieving maximal tumor shrinkage within a short time frame.The observed TTMR provides clinically relevant insights into the timing of maximal treatment benefit and may inform future treatment optimization, including induction-maintenance approaches.
No takes yet. Share an insight, caveat, or question.
Cazzaniga et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: